Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Scientists at University of Michigan describe research in cancer vaccines
August 19th, 2008
Research findings, 'Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer,' are discussed in a new report. "A pivotal obstacle to cancer immunotherapy is peripheral T cell tolerance to tumor-associated antigens (TAAs). Tolerance induction among mature T cells in the periphery operates through a variety of mechanisms, including anergy and apoptosis," investigators in the United States report. "Although Fas-FasL-mediated apoptosis is a well-defined tolerance inducing mechanism, direct evidence of its interference with TAA-specific immunity in vivo is still lacking. In this report, we used the TRAMP mouse, which...
Source: Cancer Weekly (2008-08-19)
|
